pbr111
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01209156)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f-pbr111
- 18f-pbr111
- pbr111
- pbr111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06398392 | N/A | May 2, 2024 | University of Geneva |
| NCT04263337 | Phase 1 | Mar 12, 2020 | Harvard University, Medical College of Wisconsin, University of North Carolina at Chapel Hill |
| NCT01428505 | Phase 2 | Jul 1, 2011 | GlaxoSmithKline |
| NCT01209156 | Phase 1 | Mar 1, 2010 | Institute for Neurodegenerative Disorders |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2011 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Institute for Neurodegenerative Disorders | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Geneva | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2020 |
6 organizations
Page 1 / 1